Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.
Article
CAS
PubMed
Google Scholar
Glick JH: Meeting highlights: adjuvant therapy for breast cancer. J Natl Cancer Inst. 1988, 80 (7): 471-475. 10.1093/jnci/80.7.471.
Article
CAS
PubMed
Google Scholar
Vijver van de MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347 (25): 1999-2009. 10.1056/NEJMoa021967.
Article
PubMed
Google Scholar
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351 (27): 2817-2826. 10.1056/NEJMoa041588.
Article
CAS
PubMed
Google Scholar
Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, et al: Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008, 299 (13): 1574-1587. 10.1001/jama.299.13.1574.
Article
CAS
PubMed
Google Scholar
Parise C, Brown M, Bauer K, Caggiano V: Variation among the ER, PR, and HER2 breast cancer subtypes in California. Breast Cancer Symposium: 2007; San Francisco. 2007
Google Scholar
Parise CA, Bauer KR, Brown MM, Caggiano V: Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. Breast J. 2009, 15 (6): 593-602. 10.1111/j.1524-4741.2009.00822.x.
Article
PubMed
Google Scholar
Cancer Reporting in California:Abstracting and Coding Procedures for Hospitals, California Cancer Reporting System Standards. California Cancer Registry Data Standards and Quality Control Unit. 2009, California Department of Public Health: Cancer Surveillance and Research Branch, Sacramento, CA, I:
Fritz AG: International classification of diseases for oncology: ICD-O. 2000, Geneva: World Health Organization, Geneva, vi: 239-3
Google Scholar
Greene FL, American Joint Committee on Cancer ACS: AJCC Cancer Staging Manual. 2002, New York: Springer-Verlag, 6
Chapter
Google Scholar
SEER Extent of Disease 1998. Codes and Coding Instructions. 1998, Bethesda, MD: National Cancer Institute, National Institutes of Health, Bethesda MD, 3
Collaborative Staging Task Force of the American Joint Commission on Cancer. Collaborative Staging Manual and Coding Instructions, Version 01.03.00. 2004, U.S. Department of Health and Human Services, Bethesda, MD
Seiffert JE: SEER Program Comparative Staging Guide for Cancer. 1993, Bethesda, MD: Cancer Statistics Branch Surveillance Program, Division of Cancer Prevention and Control (DCPC). National Cancer Institute (U.S.) Bethesda MD
Google Scholar
Brown CC: The statistical comparison of relative survival rates. Biometrics. 1983, 39 (4): 941-948. 10.2307/2531329.
Article
CAS
PubMed
Google Scholar
Cufer T: Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online. Ann Oncol. 2008, 19 (Suppl 7): vii-41-45
Google Scholar
Adjuvant! Online. Accessed on: January 10, 2009, [http://www.adjuvantonline.com/index.jsp]
National Comprehensive Cancer Network. Accessed on: January 10, 2009, [http://www.nccn.org/index.asp]
Iwamoto E, Fukutomi T, Akashi-Tanaka S: Validation and problems of St-Gallen recommendations of adjuvant therapy for node-negative invasive breast cancer in Japanese patients. Jpn J Clin Oncol. 2001, 31 (6): 259-262. 10.1093/jjco/hye056.
Article
CAS
PubMed
Google Scholar
Colomer R, Vinas G, Beltran M, Izquierdo A, Lluch A, Llombart-Cussac A, Alba E, Munarriz B, Martin M: Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). J Clin Oncol. 2004, 22 (5): 961-962. 10.1200/JCO.2004.99.143.
Article
CAS
PubMed
Google Scholar
Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G: Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol. 2004, 22 (18): 3685-3693. 10.1200/JCO.2004.07.018.
Article
PubMed
Google Scholar
Yau TK, Soong IS, Chan K, Chang A, Sze H, Yeung MW, Tung R, Lau S, Lee A: Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong. Breast. 2008, 17 (1): 58-63. 10.1016/j.breast.2007.06.007.
Article
CAS
PubMed
Google Scholar
Sun JM, Han W, Im SA, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ, Choe KJ, Kim NK: A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. Cancer. 2004, 101 (11): 2516-2522. 10.1002/cncr.20665.
Article
PubMed
Google Scholar
Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, et al: Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009, 16 (5): 1112-1121. 10.1245/s10434-009-0334-7.
Article
PubMed
Google Scholar
Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler JG, Elsasser A, Gehrmann M, et al: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol. 2009, 20 (2): 258-264. 10.1093/annonc/mdn590.
Article
CAS
PubMed
Google Scholar
Boyages J, Chua B, Taylor R, Bilous M, Salisbury E, Wilcken N, Ung O: Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg. 2002, 89 (6): 789-796. 10.1046/j.1365-2168.2002.02113.x.
Article
PubMed
Google Scholar
Boyages J, Taylor R, Chua B, Ung O, Bilous M, Salisbury E, Wilcken N: A risk index for early node-negative breast cancer. Br J Surg. 2006, 93 (5): 564-571. 10.1002/bjs.5207.
Article
CAS
PubMed
Google Scholar
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007, 109 (9): 1721-1728. 10.1002/cncr.22618.
Article
PubMed
Google Scholar
Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008, 112 (4): 737-747. 10.1002/cncr.23243.
Article
PubMed
Google Scholar
De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, et al: Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?. J Clin Oncol. 2008, 26 (2): 335-336. 10.1200/JCO.2007.14.8411. author reply 336-338
Article
PubMed
Google Scholar
Ibrahim M, Dodson A, Barnett S, Fish D, Jasani B, Miller K: Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol. 2008, 129 (3): 398-409. 10.1309/2YXRLEQVPPNRWHGA.
Article
CAS
PubMed
Google Scholar
Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007, 25 (30): 4772-4778. 10.1200/JCO.2007.12.2747.
Article
PubMed
Google Scholar
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20 (8): 1319-1329. 10.1093/annonc/mdp322.
Article
CAS
PubMed
PubMed Central
Google Scholar
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.
Article
CAS
PubMed
Google Scholar
Linn SC, Van't Veer LJ: Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer. 2009, 45 (Suppl 1): 11-26. 10.1016/S0959-8049(09)70012-7.
Article
PubMed
Google Scholar
Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003, 21 (1): 28-34. 10.1200/JCO.2003.03.088.
Article
CAS
PubMed
Google Scholar
Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI: Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005, 103 (11): 2241-2251. 10.1002/cncr.21030.
Article
CAS
PubMed
Google Scholar
Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9 (1): R6-10.1186/bcr1639.
Article
PubMed
PubMed Central
Google Scholar
Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, Mallon E, Colleoni M, Castiglione-Gertsch M, Regan MM, et al: Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol. 2010, 21 (2): 245-254. 10.1093/annonc/mdp317.
Article
CAS
PubMed
Google Scholar